Alpha-s1 Casein Hydrolysate on Sleep
Key facts
- Who runs it
- Kuang Tien General Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 38 people enrolled
- Started
- 1 May 2019
- Ended
- 30 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- alpha-s1 casein hydrolysate
- Maltodextrin
- Record updated
- 10 January 2024
Who can take part
- Age
- 20 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- age between 20 and 80 who meet the diagnostic criteria for chronic insomnia according to the International Classification of Sleep Disorders (ICSD) (Third Edition)
- PSQI score greater than 5
- participants must voluntarily agree to participate in the trial after explanation by a physician and complete the informed consent form
Who cannot take part
- currently using tranquilizers, hypnotics, or stimulant-related medications or substances (such as coffee or energy drinks)
- patients with a history of significant head trauma
- those with other severe medical conditions (e.g., hepatic or renal dysfunction)
- those with allergies to dairy products
- individuals with alcohol abuse within the past year
- Pregnant women or breastfeeding mothers
- participants unable to comply with the trial schedule
- individuals on a vegetarian diet
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigates the impact of Aalpha-s1 casein hydrolysate (ACH; Lactium®) on sleep quality in individuals with chronic insomnia, employing both subjective sleep profiles and objective polysomnography (PSG) recordings.
The 2 groups in the trial
- ACH (Aalpha-s1 casein hydrolysate)Treatment being tested
Each participant will take Prelactium capsules (alpha-s2 casein hydrolysate supplement; 150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.
Treatment: alpha-s1 casein hydrolysate
- Placebo (Maltodextrin)Placebo, for comparison
Each participant will take Maltodextrin capsules (150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.
Treatment: Maltodextrin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Alpha-s1 Casein Hydrolysate for Patients With Chronic Insomnia: A Randomized Double-Blind Controlled Trial
- Publications
- The impact of Alpha-s1 Casein hydrolysate on chronic insomnia: A randomized, double-blind controlled trial.Clinical nutrition (Edinburgh, Scotland), 2024
- Record updated
- 10 January 2024